MicroceLac® Plus
Premium co-processed Excipient
35 % alpha-lactose monohydrate and 65 % microcrystalline cellulose (MCC)
Co-processed excipients (CPEs) play a key role in modern pharmaceutical manufacturing by offering significantly improved functionality compared to conventional excipients. Through the physical combination of established substances – multifunctional particle systems are created with enhanced flowability, compactibility, and reduced sensitivity to lubricants. This leads to improved tablet uniformity and mechanical strength while reducing the need for additional formulation steps. Especially in direct compression, CPEs enable more efficient and robust tablet production, even with high drug loads or poorly compressible APIs. Since they are composed of pharmacopoeial-approved components, regulatory requirements are minimal, further increasing their appeal.
MicroceLac® Plus – Sets a new benchmark in tabletability
MicroceLac® Plus is an innovative addition to MEGGLE’s co-processed excipients product line, combining 35 % alpha-lactose monohydrate and 65 % microcrystalline cellulose to enhance tablet formulation. Its unique advantage is the exceptional tabletability, delivering tablet hardness that exceeds not only its individual components and their physical mixture but also standard excipients.
Designed for direct compression, it is ideal for production of robust tablets with high mechanical strength and low friability, even with challenging APIs or high drug loads. MicroceLac® Plus is the next level excipient for those who want to be sure of superior performance.
Benefits
- Outstanding tabletability: Outperforming all standard excipients on the market
- Exceptional compressibility: Enables direct compression, even for difficult APIs or high drug load
- High tablet hardness and very low friability also at high drug loads
- Synergistic effect: Tabletability of CPE even better than for single ingredients
- Good flowability in comparison with its corresponding physical blend
- No capping tendency due to ideal combination of plastic and brittle deformation
- Very smooth surface of the resulting cores for easy and economical coating
- Constant lactose/cellulose ratio: Simple and consistent dosing also in continuous manufacturing
- Reduction of tablet size: Ideal for manufacturing of easy-to-swallow, patient-friendly dosage forms
Areas of Application
- Primarily designed for direct compression (DC) and continuous direct compression (CDC).
- Direct compression of difficult APIs
- Formulations with a high API content
- Suitable for mini-tablets
- Easy and economical coating
Order your free sample!
- Dry granulation
- Direct compression
- Roller compaction
- Continuous processing
- Co-processed Excipients
- Oral Solid Dose
- Formulation with micronized API
- Formulation with poorly flowing API
- Low to high dose DC formulation
- Placebo tablet
- Tablet
- Capsule
25kg – Paper bag with PE-EVOH-PE inliner
18 months
Wasserburg am Inn, Germany
Downloads
Typical particle size distribution
Typical Product Data
- x10: 33 µm, x50: 75 µm, x90: 134 µm
- Span [(x90-x10)/x50]: 1.35
- Density bulk: 0.430 g/ml
- Density tapped: 0.530 g/ml
- Hausner Ratio: 1.24
- Carr’s Index: 18 %
Specified Product Data
Particle size distribution
Sieve Method: Air-jet sieving
- <32 µm: NMT 30%
- <63 µm: 35-70%
- <100 µm: NLT 80%
Do you have any questions or need a customised solution?